12:00 AM
Jun 10, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

Selumetinib: Phase II data

Researchers at the Memorial Sloan Kettering Cancer Center reported data from an open-label, North American Phase II trial in 98 patients with metastatic uveal melanoma showing that twice-daily 75 mg oral selumetinib met the primary endpoint of improving median PFS vs. temozolomide (15.9 vs. 7 weeks, p=0.0005). Additionally, 4- and 6-month PFS rates for selumetinib were 43.1% and 22.9%, respectively,...

Read the full 287 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >